South Korea
· Delayed Price · Currency is KRW EuBiologics Statistics
Total Valuation
EuBiologics has a market cap or net worth of KRW 509.65 billion. The enterprise value is 506.39 billion.
| Market Cap | 509.65B |
| Enterprise Value | 506.39B |
Important Dates
The last earnings date was Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
EuBiologics has 36.53 million shares outstanding. The number of shares has increased by 0.13% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 36.53M |
| Shares Change (YoY) | +0.13% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 0.06% |
| Owned by Institutions (%) | 4.90% |
| Float | 29.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.33 |
| PB Ratio | 4.57 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 26.12 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 30.96, with an EV/FCF ratio of 25.95.
| EV / Earnings | -36.49 |
| EV / Sales | 7.30 |
| EV / EBITDA | 30.96 |
| EV / EBIT | 70.46 |
| EV / FCF | 25.95 |
Financial Position
The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.14.
| Current Ratio | 1.63 |
| Quick Ratio | 0.77 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.88 |
| Debt / FCF | 0.76 |
| Interest Coverage | 15.78 |
Financial Efficiency
Return on equity (ROE) is -13.70% and return on invested capital (ROIC) is 3.78%.
| Return on Equity (ROE) | -13.70% |
| Return on Assets (ROA) | 3.07% |
| Return on Capital (ROIC) | 3.78% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.44 |
| Inventory Turnover | 2.26 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +60.54% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +60.54% |
| 50-Day Moving Average | 12,840.00 |
| 200-Day Moving Average | 12,253.40 |
| Relative Strength Index (RSI) | 46.49 |
| Average Volume (20 Days) | 1,879,286 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EuBiologics had revenue of KRW 69.37 billion and -13.88 billion in losses. Loss per share was -381.00.
| Revenue | 69.37B |
| Gross Profit | 33.96B |
| Operating Income | 7.70B |
| Pretax Income | -14.61B |
| Net Income | -13.88B |
| EBITDA | 16.87B |
| EBIT | 7.70B |
| Loss Per Share | -381.00 |
Balance Sheet
The company has 11.49 billion in cash and 14.78 billion in debt, giving a net cash position of -3.29 billion or -89.98 per share.
| Cash & Cash Equivalents | 11.49B |
| Total Debt | 14.78B |
| Net Cash | -3.29B |
| Net Cash Per Share | -89.98 |
| Equity (Book Value) | 104.82B |
| Book Value Per Share | 3,055.10 |
| Working Capital | 16.07B |
Cash Flow
In the last 12 months, operating cash flow was 26.45 billion and capital expenditures -6.94 billion, giving a free cash flow of 19.52 billion.
| Operating Cash Flow | 26.45B |
| Capital Expenditures | -6.94B |
| Free Cash Flow | 19.52B |
| FCF Per Share | 534.17 |
Margins
Gross margin is 48.96%, with operating and profit margins of 11.10% and -20.01%.
| Gross Margin | 48.96% |
| Operating Margin | 11.10% |
| Pretax Margin | -21.07% |
| Profit Margin | -20.01% |
| EBITDA Margin | 24.32% |
| EBIT Margin | 11.10% |
| FCF Margin | 28.13% |
Dividends & Yields
EuBiologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.13% |
| Shareholder Yield | -0.13% |
| Earnings Yield | -2.73% |
| FCF Yield | 3.83% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
EuBiologics has an Altman Z-Score of 3.5.
| Altman Z-Score | 3.5 |
| Piotroski F-Score | n/a |